课题基金 / 基金详情

项目摘要

项目成果

JOSEPH Benjamin RUCKER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): As the primary mechanism by which animals detect nutrient-rich foods and discriminate against toxins, the sense of taste has a significant impact on health and behavior. Bitter tastes are perceived with high sensitivity and broad specificity, and can evoke strong aversive reactions that influence health-related behaviors such as dietary preference and pharmaceutical compliance. Conversely, sweet taste facilitates the detection and consumption of high carbohydrate (and hence highly caloric) foods, but over-consumption of calories can lead to obesity and diabetes. It is therefore desirable in many circumstances to manipulate taste perception and/or to provide taste substitutes. Bitter, sweet, and umami (savory) tastes are detected at the cellular level by a family of taste receptors (TASRs), which belong to the G protein-coupled receptor (GPCR) superfamily of proteins. Because they are refractory to direct structural visualization such as x-ray crystallography, very little is known about the structural features of TASRs that are responsible for binding ligands. Elucidating TASR-ligand structural interactions could enable the development of health-related products, such as bitter blockers and sugar substitutes. The results of this proposal would enable ligands of TASRs, and possibly other GPCRs, to be developed. PUBLIC HEALTH RELEVANCE: Taste ligands are currently used to mask aversive tastes, improve patient compliance, influence choice of foods, and modify caloric intake, so routinely influence daily human activity. This proposal will contribute to human health by using a research platform to discover novel taste ligands.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Claudin MAbs for Treating Solid Tumors
  • 批准号:
    10482193
  • 项目类别:
  • 资助金额:
    $59.99万
  • 财政年份:
    2022
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Development of Claudin MAbs for Treating Solid Tumors
  • 批准号:
    10631161
  • 项目类别:
  • 资助金额:
    $70.93万
  • 财政年份:
    2022
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Development of Nav1.7 Monoclonal Antibodies for Treating Pain
  • 批准号:
    10318547
  • 项目类别:
  • 资助金额:
    $47.48万
  • 财政年份:
    2021
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Identifying Agonist MAbs against GPCRs
  • 批准号:
    9756430
  • 项目类别:
  • 资助金额:
    $13.22万
  • 财政年份:
    2018
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
海外基金